drugset / Trial / NCT00680953

Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis

NCT00680953

Phase 3 Completed 1262 enrolled Daiichi Sankyo
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluate the efficacy and safety of denosumab in the treatment of involutional (postmenopausal and senile) osteoporotic subjects with prevalent fragility vertebral fracture(s)

Timeline

Start
2008-05
Primary completion
2012-06
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alendronic Acid Small molecule 35 mg Oral
Subject Denosumab Monoclonal antibody 60 mg Subcutaneous

Indications